{"organizations": [], "uuid": "835209e0d99c0ac88c1ba02e5bae5cbdde3b0f50", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-adverum-biotechnologies-provides-2/brief-adverum-biotechnologies-provides-2018-outlook-idUSASB0BZRR", "country": "US", "domain_rank": 408, "title": "BRIEF-Adverum Biotechnologies Provides 2018 Outlook", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T16:49:00.000+02:00", "replies_count": 0, "uuid": "835209e0d99c0ac88c1ba02e5bae5cbdde3b0f50"}, "author": "", "url": "https://www.reuters.com/article/brief-adverum-biotechnologies-provides-2/brief-adverum-biotechnologies-provides-2018-outlook-idUSASB0BZRR", "ord_in_thread": 0, "title": "BRIEF-Adverum Biotechnologies Provides 2018 Outlook", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-adverum biotechnologies", "sentiment": "negative"}, {"name": "adverum biotechnologies inc", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "amd", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 49 PM / Updated 24 minutes ago BRIEF-Adverum Biotechnologies Provides 2018 Outlook Reuters Staff \nJan 4 (Reuters) - Adverum Biotechnologies Inc: * ADVERUM BIOTECHNOLOGIES PROVIDES 2018 OUTLOOK \n* ADVERUM BIOTECHNOLOGIES INC - ADVERUMâ€˜S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017. \n* ADVERUM BIOTECHNOLOGIES INC - CURRENT CASH POSITION IS EXPECTED TO FUND THREE LEAD GENE THERAPY PROGRAMS THROUGH END OF 2019 \n* ADVERUM - PLAN TO SUBMIT 2 INVESTIGATIONAL NDA WITH FDA IN H2 2018, FOR ADVM-022 IN WET AMD, ADVM-053 IN HEREDITARY ANGIOEDEMA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T16:49:00.000+02:00", "crawled": "2018-01-04T17:03:08.011+02:00", "highlightTitle": ""}